Final Evidence Report and Meeting Summary
-----------------------------------------
[https://icer-review.org/material/high-cholesterol-final-report/][1]
New Evidence Update
-------------------
[https://icer-review.org/material/pcks9-inhibitors-neu/][2]
[https://icer-review.org/material/alirocumab-final-neu/][9]
----------
## Action Guide for Clinicians, Payers, and Policymakers ##
[https://icer-review.org/material/high-cholesterol-action-guide_cpp/][3]
## Action Guide for Patients ##
[https://icer-review.org/material/high-cholesterol_action_guide_patients/][4]
----------
## Publications ##
[http://dx.doi.org/10.1001/jama.2016.11004][5]
[http://dx.doi.org/10.1001/jamainternmed.2015.7248][6]
[http://dx.doi.org/10.1001/jama.2017.9924][7]
[https://dx.doi.org/10.7326/M17-3367][8]
[1]: https://icer-review.org/material/high-cholesterol-final-report/
[2]: https://icer-review.org/material/pcks9-inhibitors-neu/
[3]: https://icer-review.org/material/high-cholesterol-action-guide_cpp/
[4]: https://icer-review.org/material/high-cholesterol_action_guide_patients/
[5]: http://dx.doi.org/10.1001/jama.2016.11004
[6]: http://dx.doi.org/10.1001/jamainternmed.2015.7248
[7]: http://dx.doi.org/10.1001/jama.2017.9924
[8]:https://dx.doi.org/10.7326/M17-3367
[9]: https://icer-review.org/material/alirocumab-final-neu/